Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.71 |
| ▸ | PLAU | P00749 | 17/20 | 0.70 |
| ▸ | PLG | P00747 | 7/20 | 0.70 |
| ▸ | PLAT | P00750 | 6/20 | 0.70 |
| ▸ | KLK1 | P06870 | 5/20 | 0.70 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771875 | 1.00 | ASIC3 (0.71) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5779092 | 0.84 | ASIC3 (0.52) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5779090 | 0.84 | ASIC3 (0.52) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL21093917 | 0.83 | ASIC3 (1.00) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL29531162 | 0.82 | PLAU (1.00) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5775814 | 0.82 | PLAU (1.00) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5775525 | 0.79 | PLAU (0.66) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5775530 | 0.79 | PLAU (0.66) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5777231 | 0.79 | ASIC3 (0.54) | ASIC3PLAUPLGPLATKLK1 | |
| SCHEMBL5777233 | 0.79 | ASIC3 (0.54) | ASIC3PLAUPLGPLATKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | claimed |
| US-6504031-B1 | Enzyme inhibitor such as 6-(2-(1-isopropyl-1,2,3,4-tetrahydro -7-isoquinolinyl)ethenyl)-2-naphthalenecarboximidamide, used as angiogenesis inhibitors; antiarthritic, antiinflammatory and antitumor agents | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | claimed |
| US-6495562-B1 | SUCH AS 6-(2-(4,4-DIETHYL-1-ISOPROPYL-3,4-DIHYDRO-6-ISOQUINOLINYL)CYCLOPROPYL)-2 -NAPHTHALENECARBOXIMIDAMIDE | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| US-20190167675-A1 | METHODS AND COMPOSITIONS FOR APPETITE CONTROL AND WEIGHT MANAGEMENT | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| WO-2018027550-A1 | METHODS AND COMPOSITIONS FOR APPETITE CONTROL AND WEIGHT MANAGEMENT | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2018-02-15 | — | — | WO | disclosed |
| EP-1276722-B1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6504031-B1 | Enzyme inhibitor such as 6-(2-(1-isopropyl-1,2,3,4-tetrahydro -7-isoquinolinyl)ethenyl)-2-naphthalenecarboximidamide, used as angiogenesis inhibitors; antiarthritic, antiinflammatory and antitumor agents | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| US-6495562-B1 | SUCH AS 6-(2-(4,4-DIETHYL-1-ISOPROPYL-3,4-DIHYDRO-6-ISOQUINOLINYL)CYCLOPROPYL)-2 -NAPHTHALENECARBOXIMIDAMIDE | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167675-A1 | METHODS AND COMPOSITIONS FOR APPETITE CONTROL AND WEIGHT MANAGEMENT | GIPR, GLP1R, GPR119 | ASIC3 79/4885PLAU 4100/4885PLG 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.